StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $9.00 price objective on shares of Trevena in a research report on Tuesday, April 2nd.

Trevena Stock Down 3.2 %

Shares of TRVN stock opened at $0.43 on Wednesday. Trevena has a 12 month low of $0.30 and a 12 month high of $2.80. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 8.35. The firm has a market cap of $7.80 million, a PE ratio of -0.14 and a beta of 1.11. The stock has a 50 day moving average of $0.46 and a 200-day moving average of $0.56.

Trevena (NASDAQ:TRVN) last announced its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The company had revenue of ($0.08) million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts predict that Trevena will post -1.28 EPS for the current year.

Institutional Trading of Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new position in Trevena, Inc. (NASDAQ:TRVN) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned 0.32% of Trevena at the end of the most recent reporting period. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.